Skip to main
ANGO

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc has been successfully expanding its Auryon product's customer base in both out-of-hospital and hospital settings, which is positively impacting average selling prices (ASP). The company is also on track to enhance its gross margins to 52.5% through accelerated manufacturing initiatives and a favorable shift toward higher Med-Tech revenue. Additionally, management projects sustained growth driven by new customer acquisitions, increased utilization within existing accounts, and a recent ability to raise pricing on its offerings.

Bears say

AngioDynamics Inc is facing significant financial challenges, including anticipated tariff headwinds estimated between $4 million and $6 million, which could negatively impact revenue projections. Additionally, the company expects its second half of fiscal year 2026 inventory to be pressured by rising raw material costs, indicating potential margin shrinkage. Despite recent successes with capital sales and strong demand for NanoKnife disposables, these operational and cost pressures could undermine the company’s long-term financial stability.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.